Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: An updated meta-analysis

Thrombosis Research

Volumn 128, Issue 6, 2011, Pages 593-594

  Liu, Yan Ping ^a   Hao, Pan Pan ^b   Zhang, Ming Xiang ^b   Zhang, Cheng ^b   Gao, Fei ^b   Zhang, Yun ^b   Chen, Yu Guo ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19;

ACUTE CORONARY SYNDROME; ALLELE; CARDIOVASCULAR DISEASE; GAIN OF FUNCTION MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LETTER; LOSS OF FUNCTION MUTATION; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACUTE CORONARY SYNDROME; ARYL HYDROCARBON HYDROXYLASES; HUMANS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 81155145167     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.07.003     Document Type: Letter

References (22)

1. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
2. G. Paré, S.R. Mehta, S. Yusuf, S.S. Anand, S.J. Connolly, and J. Hirsh Effects of CYP2C19 genotype on outcomes of clopidogrel treatment N Engl J Med 363 2010 1704 1714
3. L. Wallentin, S. James, R.F. Storey, M. Armstrong, B.J. Barratt, and J. Horrow Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 2010 1320 1328
4. T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, and N. Méneveau Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
5. K.A. Tiroch, D. Sibbing, W. Koch, T. Roosen-Runge, J. Mehilli, and A. Schömig Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events Am Heart J 160 2010 506 512
6. L.A. Malek, B. Kisiel, M. Spiewak, M. Grabowski, K.J. Filipiak, and G. Kostrzewa Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel Circ J 72 2008 1165 1169 (Pubitemid 351957086)
7. D. Trenk, W. Hochholzer, M.F. Fromm, L.E. Chialda, A. Pahl, and C.M. Valina Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934 (Pubitemid 351636443)
8. J.P. Collet, J.S. Hulot, A. Pena, E. Villard, J.B. Esteve, and J. Silvain Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
9. B. Giusti, A.M. Gori, R. Marcucci, C. Saracini, I. Sestini, and R. Paniccia Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis Am J Cardiol 103 2009 806 811
10. A.R. Shuldiner, J.R. O'Connell, K.P. Bliden, A. Gandhi, K. Ryan, and R.B. Horenstein Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
11. D. Sibbing, J. Stegherr, W. Latz, W. Koch, J. Mehilli, and K. Dörrler Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 2009 916 922
12. L.A. Małek, J. Przyłuski, M. Spiewak, M. Kłopotowski, G. Kostrzewa, and M. Kruk Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction Cardiology 117 2010 81 87
13. T. Sawada, T. Shinke, J. Shite, T. Honjo, Y. Haraguchi, and R. Nishio Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel Circ J 75 2011 99 105
14. K. Yamamoto, S. Hokimoto, T. Chitose, K. Morita, T. Ono, and K. Kaikita Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy J Cardiol 57 2011 194 201
15. D. Sibbing, W. Koch, D. Gebhard, T. Schuster, S. Braun, and J. Stegherr Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518
16. A.M. Harmsze, J.W. van Werkum, J.M. Ten Berg, B. Zwart, H.J. Bouman, and N.J. Breet CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study Eur Heart J 31 2010 3046 3053
17. J.L. Mega, J.V. Thakuria, C.P. Cannon, and M.S. Sabatine Sequence variations in CYP metabolism genes and cardiovascular outcomes following treatment with clopidogrel: insights from the CLARITY-TIMI 28 genomic study (abstr) J Am Coll Cardiol 51 Suppl. A 2008 A206
18. J.L. Anderson, C.P. Mower, B.D. Horne, J.B. Muhlestein, J.J. Park, and T.L. Bair Carriage of the CYP2C19*2 allele increases one-year risk of myocardial infarction among recipients of drug-eluting stents treated with clopidogrel (abstr) J Am Coll Cardiol 53 Suppl. A 2009 A27
19. A. Worrall, A. Armesilla, M. Norell, S. Khogali, M. Cusack, and A. Smallwood The presence of the CYP p450 C19*2 allele is associated with impaired response to clopidogrel as measured by the VerifyNow P2Y12 near-patient testing device in patients undergoing coronary angiography (abstr) Eur Heart J 30 2009 327 Suppl.
20. D.L. Bhatt Charisma Genomic Substudy Paper presented at: Annual Meeting of Transcatheter Cardiovascular Therapeutics; September 24, 2009; San Francisco, CA 2009
21. J.L. Mega, T. Simon, J.P. Collet, J.L. Anderson, E.M. Antman, and K. Bliden Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 2010 1821 1830
22. J.S. Hulot, J.P. Collet, J. Silvain, A. Pena, A. Bellemain-Appaix, and O. Barthélémy Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis J Am Coll Cardiol 56 2010 134 143